ÂÜÀòÂÒÂ×

Andrew Nash is Senior Vice President, Research at CSL Limited. He completed his PhD in immunology at The University of Melbourne in 1988 and, after moving to the Centre for Animal Biotechnology in the Faculty of Veterinary Science, developed and led a research group focused on basic and applied aspects of cytokine biology.

In 1996 he joined the ASX listed biotechnology company Zenyth Therapeutics (then Amrad Corporation) as a senior scientist and subsequently held a number of positions including Director of Biologicals Research and Chief Scientific Officer. In July of 2005 he was appointed Chief Executive Officer of Zenyth, a position which he held up until the acquisition of Zenyth by CSL Limited in November 2006.

Following the acquisition he was appointed as CSL’s SVP, Research and is currently based at the Bio21 Institute where he leads a large global effort focused on the discovery and development of new protein-based medicines to treat serious human disease.